Article
mRNA cancer vaccines: Advances, trends and challenges
23 Mar 2022
Abstract excerpt
Patients exhibit good tolerance to messenger ribonucleic acid (mRNA) vaccines, and the choice of encoded molecules is flexible and diverse. These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex (MHC) restriction, are relatively easy to control and can be rapidly mass produced. In 2021, the U.S. Food and Drug Administration (FDA)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
